Last reviewed · How we verify

fenofibrate + rosuvastatin — Competitive Intelligence Brief

fenofibrate + rosuvastatin (fenofibrate + rosuvastatin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fibrate + HMG-CoA reductase inhibitor (statin). Area: Cardiovascular.

marketed Fibrate + HMG-CoA reductase inhibitor (statin) PPAR-α; HMG-CoA reductase Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

fenofibrate + rosuvastatin (fenofibrate + rosuvastatin) — University of Campania Luigi Vanvitelli. Fenofibrate activates PPAR-alpha to reduce triglycerides and increase HDL, while rosuvastatin inhibits HMG-CoA reductase to lower LDL cholesterol.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
fenofibrate + rosuvastatin TARGET fenofibrate + rosuvastatin University of Campania Luigi Vanvitelli marketed Fibrate + HMG-CoA reductase inhibitor (statin) PPAR-α; HMG-CoA reductase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fibrate + HMG-CoA reductase inhibitor (statin) class)

  1. University of Campania Luigi Vanvitelli · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). fenofibrate + rosuvastatin — Competitive Intelligence Brief. https://druglandscape.com/ci/fenofibrate-rosuvastatin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: